Categories: AnalyticsBioTechDataDesignDrugHealthTechPlatformRoboticsTechnology
Bispecific antibodies are the next breakthrough in cancer therapy, but current R&D is limited by a lack of scalable and flexible design platforms. LiliumX overcomes this limitation by using a modular protein platform, rapidly generating and testing thousands of candidate bispecifics using robotic screening and big data analysis to discover bispecific lead assets with entirely new modes of action.
Investors 4
Mentions in press and media 1
Reviews 0
